Citius Pharmaceuticals, Inc. (CTXR)
Market Closed
17 Jul, 20:00
NASDAQ (CM) NASDAQ (CM) Primary 
XMUN $
0. 50
-0.01
-2.9354%
$
6.51M Market Cap
- P/E Ratio
- Div Yield
285,400 Volume
0.03 Eps
$ 0.51
Previous Close Want to track CTXR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
CTXR closed yesterday lower at $0.5, a decrease of -2.9354% from Thursday's close, completing a monthly decrease of -23.6923% or -$0.15. Over the past 12 months, CTXR stock lost -34.8226%.
CTXR is not paying dividends to its shareholders.
The last earnings report, released on May 13, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.0533%, based on the last three reports.
Citius Pharmaceuticals, Inc. has completed 4 stock splits, with the recent split occurring on Nov 26, 2024.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).
CTXR Chart
Why Is Citius Pharmaceuticals (CTXR) Stock Up 11% Today?
Citius Pharmaceuticals (NASDAQ: CTXR ) stock is on the rise Tuesday after the company announced new results from its Phase 3 clinical trial of Mino-Lok. Mino-Lok is Citius Pharmaceuticals' antibiotic lock solution for patients with central line-associated infections or catheter-related bloodstream infections.
Investorplace | 2 years ago
Citius Pharmaceuticals, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| KMT Kirk M. Tokheim Ameritas Advisory Services LLC | 1,000 | $900 | $527.7 | -$372.3 | -41.37% |
| WJ William Jollie Quent Capital LLC | 4,265 | $3,774.73 | $2,240.4 | -$1,534.33 | -40.65% |
 Leanne Menzel Smallwood Wealth Investment Management LLC | 120 | $178.8 | $63.04 | -$115.76 | -64.74% |
| MA Marie-Andree Alain Federation des caisses Desjardins du Quebec | 80 | $119 | $40.25 | -$78.75 | -66.18% |
 Joe Miller Miller Financial Services LLC | 14,000 | $12,600 | $7,280 | -$5,320 | -42.22% |
Citius Pharmaceuticals, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Vernon Bernardino HC Wainwright & Co. | -594,568.05 | $1.91M | $315,775.09 | $1.6M | 83.51% |
Citius Pharmaceuticals, Inc. (CTXR) FAQ
What is the stock price today?
The current price is $0.50.
On which exchange is it traded?
Citius Pharmaceuticals, Inc. is listed on NASDAQ (CM).
What is its stock symbol?
The ticker symbol is CTXR.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 6.51M.
Has Citius Pharmaceuticals, Inc. ever had a stock split?
Citius Pharmaceuticals, Inc. had 4 splits and the recent split was on Nov 26, 2024.
Citius Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Leonard L. Mazur CEO | NASDAQ (CM) Exchange | 17322U306 CUSIP |
| US Country | 23 Employees | 9 Jun 2017 Last Dividend | 26 Nov 2024 Last Split | 6 Jul 2017 IPO Date |
Overview
Citius Pharmaceuticals, Inc. is a late-stage pharmaceutical company specialized in developing and commercializing critical care products with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Since its foundation in 2007, Citius has concentrated on addressing unmet medical needs through a robust pipeline of proprietary products. It embarks on creating innovative solutions in the healthcare space, aiming to improve the lives of patients dealing with severe diseases. Headquartered in Cranford, New Jersey, Citius is dedicated to progressing its clinical trials to bring groundbreaking therapies to market.
Products and Services
- LYMPHIR: An engineered IL-2 diphtheria toxin fusion protein designed for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. LYMPHIR is at the forefront of Citius's oncology pipeline, currently in a Phase 3 clinical trial, aiming to provide a novel therapeutic option for a challenging form of cancer.
- Mino-Lok: An antibiotic lock solution aimed at treating patients with catheter-related bloodstream infections by salvaging the infected catheter. Mino-Lok, now in Phase 3 clinical trial, represents Citius’s approach to combating serious infections and reducing the need for catheter replacements.
- Halo-Lido: A corticosteroid-lidocaine topical formulation in a clinical Phase 2b trial. This product is designed to offer anti-inflammatory and anesthetic relief for individuals suffering from hemorrhoids, showcasing Citius’s commitment to addressing common yet often neglected conditions.
- Mino-Wrap: A liquifying gel-based wrap intended for the reduction of tissue expander infections following breast reconstructive surgeries. Mino-Wrap exemplifies Citius’s dedication to improving postoperative outcomes and enhancing the quality of care in reconstructive surgery.
- NoveCite: A mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. NoveCite represents Citius’s foray into the burgeoning field of cell therapy, emphasizing the company’s commitment to pioneering treatments for critical care and respiratory diseases.
Contact Information
Address: 11 Commerce Drive
Phone: 908 967 6677
Website: https://www.citiuspharma.com
